Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China

Wu，Zhao1; Cui，Lifeng2,3; Qian，Junlin4; Luo，Laihui5; Tu，Shuju5; Cheng，Fei1; Yuan，Lebin1; Zhang，Wen Jian2; Lin，Wei4; Tang，Hongtao4; Li，Xiaodong1; Li，Hui6; Zhang，Yang5; Zhu，Jisheng5; Li，Yong5; Xiong，Yuanpeng5; Hu，Zemin4; Peng，Peng4; He，Yongzhu5; Liu，Liping2; He，Kun4; Shen，Wei1

2023-04-07

10.1186/s12885-023-10802-9

BMC cancer   影响因子和分区

1471-2407

BACKGROUND: The survival benefit of adjuvant transarterial chemoembolization (TACE) in patients with hepatectomy for hepatocellular carcinoma (HCC) after hepatectomy remains controversial. We aimed to investigate the survival efficacy of adjuvant TACE after hepatectomy for HCC. METHODS: 1491 patients with HCC who underwent hepatectomy between January 2018 and September 2021 at four medical centers in China were retrospectively analyzed, including 782 patients who received adjuvant TACE and 709 patients who did not receive adjuvant TACE. Propensity score matching (PSM) (1:1) was performed to minimize selection bias, which balanced the clinical characteristics of the two groups. RESULTS: A total of 1254 patients were enrolled after PSM, including 627 patients who received adjuvant TACE and 627 patients who did not receive adjuvant TACE. Patients who received adjuvant TACE had higher disease-free survival (DFS, 1- ,2-, and 3-year: 78%-68%-62% vs. 69%-57%-50%, p < 0.001) and overall survival (OS, 1- ,2-, and 3-year: 96%-88%-80% vs. 90%-77%-66%, p < 0.001) than those who did not receive adjuvant TACE (Median DFS was 39 months). Among the different levels of risk factors affecting prognosis [AFP, Lymphocyte-to-monocyte ratio, Maximum tumor diameter, Number of tumors, Child-Pugh classification, Liver cirrhosis, Vascular invasion (imaging), Microvascular invasion, Satellite nodules, Differentiation, Chinese liver cancer stage II-IIIa], the majority of patients who received adjuvant TACE had higher DFS or OS than those who did not receive adjuvant TACE. More patients who received adjuvant TACE accepted subsequent antitumor therapy such as liver transplantation, re-hepatectomy and local ablation after tumor recurrence, while more patients who did not receive adjuvant TACE accepted subsequent antitumor therapy with TACE after tumor recurrence (All p < 0.05). CONCLUSIONS: Adjuvant TACE may be a potential way to monitor early tumor recurrence and improve postoperative survival in patients with HCC.

Adjuvant transarterial chemoembolization (TACE) Hepatectomy Hepatocellular carcinoma(HCC) Prognosis

SCI

英语

其他

National Natural Science Foundation of China[81860432];

Oncology

Oncology

WOS:000963553400001

BMC

CLINICAL MEDICINE

2-s2.0-85151968276

Scopus

1.Department of General Surgery,Second Clinical Medical College of Nanchang University,Second Affiliated Hospital of Nanchang University,Jiangxi Province,No.1 Minde Road,330006,China
2.Division of Hepatobiliary and Pancreas Surgery,Department of General Surgery,Second Clinical Medical College,First Affiliated Hospital,Shenzhen People's Hospital,Jinan University,Southern University of Science and Technology),No. 1017,Guangdong Province,Dongmen North Road,518020,China
3.Maoming People's Hospital,Mao Ming Shiy,China
4.Department of Hepatobiliary Surgery,Zhongshan People's Hospital (Zhongshan Hospital Affiliated to Sun Yat-sen University),Guangdong Province,No. 2 ,Sunwen East Road,528400,China
5.Division of Hepatobiliary and Pancreas Surgery,Department of General Surgery,First Clinical Medical College of Nanchang University,First Affiliated Hospital of Nanchang University,Jiangxi Province,No. 17 Yongwaizheng Street,330006,China
6.School of Public Health,Nanchang University,Nanchang,China

Wu，Zhao,Cui，Lifeng,Qian，Junlin,et al. Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China[J]. BMC cancer,2023,23(1).

Wu，Zhao.,Cui，Lifeng.,Qian，Junlin.,Luo，Laihui.,Tu，Shuju.,...&Shen，Wei.(2023).Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China.BMC cancer,23(1).

Wu，Zhao,et al."Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China".BMC cancer 23.1(2023).